Liersch, Torsten

[["dc.bibliographiccitation.journal","Oncology Research and Treatment"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Ruehlmann, Felix"],["dc.contributor.author","Nietert, Manuel M."],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.date.accessioned","2018-11-07T09:34:12Z"],["dc.date.available","2018-11-07T09:34:12Z"],["dc.date.issued","2014"],["dc.identifier.isi","000343816900255"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32127"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Karger"],["dc.publisher.place","Basel"],["dc.title","SRC expression in locally advanced rectal cancer-before and after neoadjuvant chemoradiotherapy"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1008"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","International Journal of Radiation Oncology*Biology*Physics"],["dc.bibliographiccitation.lastpage","1019"],["dc.bibliographiccitation.volume","67"],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Roedel, Claus"],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Raab, Rudolf"],["dc.contributor.author","Hess, Clemens"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Becker, Heinz"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Hutter, Matthias"],["dc.contributor.author","Hager, Eva"],["dc.contributor.author","Karstens, Johann"],["dc.contributor.author","Ewald, Hermann"],["dc.contributor.author","Christen, Norbert"],["dc.contributor.author","Jagoditsch, Michael"],["dc.contributor.author","Martus, Peter"],["dc.contributor.author","Sauer, Rolf"],["dc.date.accessioned","2018-11-07T11:04:07Z"],["dc.date.available","2018-11-07T11:04:07Z"],["dc.date.issued","2007"],["dc.description.abstract","Purpose: The impact of the delivery of radiotherapy (RT) on treatment results in rectal cancer patients is unknown. Methods and Materials: The data from 788 patients with rectal cancer treated within the German CAO/AIO/ARO-94 phase III trial were analyzed concerning the impact of the delivery of RT (adequate RT: minimal radiation RT dose delivered, 4300 cGy for neoadjuvant RT or 4700 cGy for adjuvant RT; completion of RT in < 44 days for neoadjuvant RT or < 49 days for adjuvant RT) in different centers on the locoregional recurrence rate (LRR) and disease-free survival (DFS) at 5 years. The LRR, DFS, and delivery of RT were analyzed as endpoints in multivariate analysis. Results: A significant difference was found between the centers and the delivery of RT. The overall delivery of RT was a prognostic factor for the LRR (no RT, 29.6% +/- 7.8%; inadequate RT, 21.2% +/- 5.6%; adequate RT, 6.8% +/- 1.4%; p = 0.0001) and DFS (no RT, 55.1% +/- 9.1%; inadequate RT, 57.4% +/- 6.3%; adequate RT, 69.1% +/- 2.3%; p = 0.02). Postoperatively, delivery of RT was a prognostic factor for LRR on multivariate analysis (together with pathologic stage) but not for DFS (independent parameters, pathologic stage and age). Preoperatively, on multivariate analysis, pathologic stage, but not delivery of RT, was an independent prognostic parameter for LRR and DFS (together with adequate chemotherapy). On multivariate analysis, the treatment center, treatment schedule (neoadjuvant vs. adjuvant RT), and gender were prognostic parameters for adequate RT. Conclusion: Delivery of RT should be regarded as a prognostic factor for LRR in rectal cancer and is influenced by the treatment center, treatment schedule, and patient gender. (c) 2007 Elsevier Inc."],["dc.identifier.doi","10.1016/j.ijrobp.2006.10.020"],["dc.identifier.isi","000245021100008"],["dc.identifier.pmid","17197130"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/51762"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.publisher.place","New york"],["dc.relation.conference","25th Congress of the European-Society-for-Therapeutic-Radiology-and-Oncology"],["dc.relation.eventlocation","Leipzig, GERMANY"],["dc.relation.issn","0360-3016"],["dc.title","Rectal cancer delivery of radiotherapy in adequate time and with adequate dose is influenced by treatment center, treatment schedule, and gender and is prognostic parameter for local control: Results of study CAO/ARO/AIO-94"],["dc.type","conference_paper"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Cellular Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Ried, Thomas"],["dc.contributor.author","Grade, Marian"],["dc.contributor.author","Heselmeyer-Haddad, Kerstin"],["dc.contributor.author","Camps, Jordi"],["dc.contributor.author","Hummon, Amanda"],["dc.contributor.author","Emons, Georg"],["dc.contributor.author","Auer, Gert"],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Difilippantonio, Michael J."],["dc.contributor.author","Ghadimi, B. Michael"],["dc.date.accessioned","2018-11-07T11:19:37Z"],["dc.date.available","2018-11-07T11:19:37Z"],["dc.date.issued","2008"],["dc.format.extent","91"],["dc.identifier.isi","000254301100002"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55325"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Ios Press"],["dc.publisher.place","Amsterdam"],["dc.relation.conference","Meeting of the International-Society-for-Cellular-Oncology (ISCO 2008)"],["dc.relation.eventlocation","Amsterdam, NETHERLANDS"],["dc.relation.issn","1570-5870"],["dc.title","Exploiting the genome and transcriptome for individualized cancer diagnosis and treatment stratification"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S142"],["dc.bibliographiccitation.journal","Radiotherapy and Oncology"],["dc.bibliographiccitation.volume","127"],["dc.contributor.author","Fokas, E."],["dc.contributor.author","Fietkau, R."],["dc.contributor.author","Hartmann, A."],["dc.contributor.author","Hohenberger, W."],["dc.contributor.author","Grützmann, R."],["dc.contributor.author","Ghadimi, M."],["dc.contributor.author","Liersch, T."],["dc.contributor.author","Ströbel, P."],["dc.contributor.author","Grabenbauer, G."],["dc.contributor.author","Wittekind, C."],["dc.contributor.author","Sauer, R."],["dc.contributor.author","Kaufmann, M."],["dc.contributor.author","Hothorn, T."],["dc.contributor.author","Rödel, C."],["dc.date.accessioned","2020-12-10T15:21:57Z"],["dc.date.available","2020-12-10T15:21:57Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1016/S0167-8140(18)30588-7"],["dc.identifier.issn","0167-8140"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/73225"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","OC-0278: NAR score as surrogate for disease-free survival in the CAO/ARO/AIO-04 phase 3 rectal cancer trial"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","550"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","British Journal of Surgery"],["dc.bibliographiccitation.lastpage","557"],["dc.bibliographiccitation.volume","101"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Bleckmann, Annalen"],["dc.contributor.author","Helms, H.-J."],["dc.contributor.author","Lordick, Florian"],["dc.contributor.author","Rueschoff, Josef"],["dc.contributor.author","Conradi, L.-C."],["dc.contributor.author","Sprenger, T."],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Liersch, Thorsten"],["dc.date.accessioned","2018-11-07T09:41:56Z"],["dc.date.available","2018-11-07T09:41:56Z"],["dc.date.issued","2014"],["dc.description.abstract","Background: Multidisciplinary discussion of the treatment of patients with colorectal liver metastases (CRLM) is advocated currently. The aim of this study was to investigate medical oncologists' and surgeons' assessment of resectability and indication for chemotherapy, and the effect of an educational intervention on such assessment. Methods: Medical histories of 30 patients with CRLM were presented to ten experienced medical oncologists and 11 surgeons at an initial virtual tumour board meeting (TB1). Treatment recommendations were obtained from each participant by voting for standardized answers. Following lectures on the potential of chemotherapy and surgery, assessment was repeated at a second virtual tumour board meeting (TB2), using the same patients and participants. Results: Overall, 630 answers (21 x 30) were obtained per tumour board meeting. At TB1, resectability was expected more frequently by surgeons. Participants changed 56.8 per cent of their individual answers at TB2. Assessment shifted from potentially resectable to resectable CRLM in 81 of 161 and from unresectable to (potentially) resectable CRLM in 29 of 36 answers. Preoperative chemotherapy was indicated more often by medical oncologists, and overall was included in 260 answers (41.3 per cent) at TB1, compared with only 171 answers (27.1 per cent) at TB2. Medical oncologists more often changed their decision to primary resection in resectable patients (P = 0.006). Postoperative chemotherapy was included in 51.9 and 52.4 per cent of all answers at TB1 and TB2 respectively, with no difference in changes between medical oncologists and surgeons (P = 0.980). Conclusion: Resectability and indication for preoperative chemotherapy were assessed differently by medical oncologists and surgeons. The educational intervention resulted in more patients deemed resectable by both oncologists and surgeons, and less frequent indication for chemotherapy."],["dc.description.sponsorship","Merck Serono GmbH, Germany"],["dc.identifier.doi","10.1002/bjs.9436"],["dc.identifier.isi","000332700100017"],["dc.identifier.pmid","24756914"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33842"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1365-2168"],["dc.relation.issn","0007-1323"],["dc.title","Discrepancies between medical oncologists and surgeons in assessment of resectability and indication for chemotherapy in patients with colorectal liver metastases"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Sauer, R."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Merkel, S."],["dc.contributor.author","Becker, H."],["dc.contributor.author","Hohenberger, Werner"],["dc.contributor.author","Witzigmann, Helmut"],["dc.contributor.author","Hess, C. F."],["dc.contributor.author","Fietkau, Rainer"],["dc.contributor.author","Wittekind, Christian"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T08:56:08Z"],["dc.date.available","2018-11-07T08:56:08Z"],["dc.date.issued","2011"],["dc.identifier.isi","000208880300290"],["dc.identifier.pmid","28020337"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/23066"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: Results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Folprecht, Gunnar"],["dc.contributor.author","Gruenberger, Thomas"],["dc.contributor.author","Hartmann, Joerg Thomas"],["dc.contributor.author","Lordick, Florian"],["dc.contributor.author","Stoehlmacher, Jan"],["dc.contributor.author","Bechstein, Wolf O."],["dc.contributor.author","Ockert, Detlev"],["dc.contributor.author","Herrmann, Thomas R."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Koehne, Claus-Henning"],["dc.date.accessioned","2018-11-07T11:11:03Z"],["dc.date.available","2018-11-07T11:11:03Z"],["dc.date.issued","2008"],["dc.format.extent","168"],["dc.identifier.isi","000259973300509"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53345"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","33rd European-Society-for-Medical-Oncology Congress"],["dc.relation.eventlocation","Stockholm, SWEDEN"],["dc.relation.issn","0923-7534"],["dc.title","RANDOMIZED MULTICENTER STUDY OF CETUXIMAB PLUS FOLFOX OR PLUS FOLFIRI IN NEOADJUVANT TREATMENT OF NON-RESECTABLE COLORECTAL LIVER METASTASES (CELIM-STUDY)"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","95"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","European Journal of Cancer"],["dc.bibliographiccitation.lastpage","101"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Winzer, K.-J."],["dc.contributor.author","Sauerbrei, W."],["dc.contributor.author","Braun, M."],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Dunst, J."],["dc.contributor.author","Guski, Hans"],["dc.contributor.author","Schumacher, M."],["dc.date.accessioned","2018-11-07T08:47:34Z"],["dc.date.available","2018-11-07T08:47:34Z"],["dc.date.issued","2010"],["dc.description.abstract","To study the role of radiotherapy and tamoxifen after breast-conserving surgery (BCS) in patients with a favourable prognosis, a clinical trial was initiated by the German Breast Cancer Study Group (GBSG-V). Between 1991 and 1998, 361 patients (pT 1pN0M0, aged 45-75 years, receptor positive, grades I and II) were randomised to radiotherapy (yes/no) and tamoxifen for 2 years (yes/no) in a 2 x 2-factorial design; the exclusion of seven centres (14 patients) left 347 patients for the analysis. First results after a median follow-up of 5.9 years were published. Herein we present updated results after a median follow-up of about 10 years. Hundred and eleven events concerning event-free survival (EFS) have been observed. Since a strong interactive effect between radiotherapy and tamoxifen has been established, the results are presented in terms of the treatment effects for all four treatment groups separately. Mainly due to the presence of local recurrences, the event rate was much higher in the group with BCS only than in the other three groups. No significant difference could be established between the four treatment groups for distant disease-free survival rates (DDFS). Updated results give further evidence that even in patients with a favourable prognosis, the avoidance of radiotherapy and tamoxifen after BCS increases the rate of local recurrences substantially. Rates are about three times higher in the BCS only group. For the two outcomes EFS and DDFS, no important difference could be seen between the three groups with an additional treatment. However, because of the limited sample size with corresponding low power the strength of evidence for such a comparison is weak. (C) 2009 Elsevier Ltd. All rights reserved."],["dc.description.sponsorship","Deutsche Krebshilfe e.V."],["dc.identifier.doi","10.1016/j.ejca.2009.10.007"],["dc.identifier.isi","000274103600013"],["dc.identifier.pmid","19879131"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20987"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Sci Ltd"],["dc.relation.issn","1879-0852"],["dc.relation.issn","0959-8049"],["dc.title","Radiation therapy and tamoxifen after breast-conserving surgery: Updated results of a 2 x 2 randomised clinical trial in patients with low risk of recurrence"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.volume","187"],["dc.contributor.author","Roedel, Franz"],["dc.contributor.author","Sprenger, Thilo"],["dc.contributor.author","Beißbarth, Tim"],["dc.contributor.author","Conradi, Lena-Christin"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Homayonfaur, K."],["dc.contributor.author","Wolff, Hendrik Andreas"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Yildirim, Muejdat"],["dc.contributor.author","Becker, H."],["dc.contributor.author","Liersch, Torsten"],["dc.contributor.author","Roedel, Claus"],["dc.date.accessioned","2018-11-07T08:55:28Z"],["dc.date.available","2018-11-07T08:55:28Z"],["dc.date.issued","2011"],["dc.format.extent","46"],["dc.identifier.isi","000291236200125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22909"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.publisher.place","Munich"],["dc.relation.conference","17th Annual Meeting of the German-Society-for-Radiation-Oncology"],["dc.relation.eventlocation","Wiesbaden, GERMANY"],["dc.relation.issn","0179-7158"],["dc.title","A lack of down-regulation of survivin after neoadjuvant Chemoradiotherapy for Rectal cancer with distant metastasis and Reduced survival rate linked"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","127"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Strahlentherapie und Onkologie"],["dc.bibliographiccitation.lastpage","133"],["dc.bibliographiccitation.volume","185"],["dc.contributor.author","Vorwerk, Hilke"],["dc.contributor.author","Liersch, Thorsten"],["dc.contributor.author","Rothe, Hilka"],["dc.contributor.author","Ghadimi, Michael B."],["dc.contributor.author","Christiansen, Hans"],["dc.contributor.author","Hess, Clemens Friedrich"],["dc.contributor.author","Hermann, Robert Michael"],["dc.date.accessioned","2018-11-07T08:33:20Z"],["dc.date.available","2018-11-07T08:33:20Z"],["dc.date.issued","2009"],["dc.description.abstract","In locally advanced rectal cancer, neoadjuvant radiochemotherapy is indicated. To improve target volume definition for radiotherapy planning, the potential of implanted gold markers in the tumor region was evaluated. In nine consecutive patients, two to three gold markers were implanted in the tumor region during rigid rectoscopy. Computed tomography scans were performed during treatment planning. All electronic portal imaging devices (EPIDs) recorded during treatment series were analyzed. All patients underwent complete tumor resection with meticulous histopathologic examination. The gold markers could easily be implanted into the mesorectal tissue at the caudal tumor border without any complications. They were helpful in identifying the inferior border of the planning target volume in order to spare normal tissue (in particular anal structures). No significant shift of the markers was found during the course of therapy. Marker matching of the EPIDs did not improve patient positioning in comparison to bone structure matching. The former position of at least one marker could be identified in all patients during histopathologic examination. The use of gold marker enables a more precise definition of the target volume for radiotherapy in patients with rectal cancer. This could eventually allow a better protection of anal structures of patients with a tumor localization a parts per thousand yen 5 cm cranial of the anal sphincter. The implantation of the gold markers improved communication between the surgeon, the radiooncologist and the pathologist resulting in intensified exchange of relevant informations."],["dc.description.sponsorship","German scientific community"],["dc.identifier.doi","10.1007/s00066-009-1928-5"],["dc.identifier.isi","000263686200007"],["dc.identifier.pmid","19241000"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/17553"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Urban & Vogel"],["dc.relation.issn","0179-7158"],["dc.title","Goldmarker zur Tumorlokalisation und Zielvolumendefinition bei der Strahlentherapie des Rektumkarzinoms"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]